- Mixed Q1 2026 Financials: ADC Therapeutics SA (NYSE:ADCT) reported a mixed first quarter with an earnings per share (EPS) miss of -$0.21 but an improved loss year-over-year, alongside a slight revenue beat of $20.03 million.
- Strong Liquidity Despite Unprofitability: The biotechnology company maintains a robust current ratio of 4.09 and a significant cash position with $231 million in cash and equivalents, providing a cash runway into 2028, despite a negative Price-to-Earnings (P/E) ratio of -4.19 indicating current unprofitability.
- Focus on Clinical Development: ADC Therapeutics continues to advance its pipeline of targeted cancer drugs, with key data expected from LOTIS-5 and LOTIS-7 clinical trials by year-end, underscoring its commitment to developing treatments for hematologic malignancies and solid tumors.
ADC Therapeutics SA (NYSE:ADCT) is a biotechnology company that focuses on developing antibody-drug conjugates (ADCs). These are a class of targeted cancer drugs. The company’s activities center around its ZYNLONTA program and other clinical trials aimed at treating patients with hematologic malignancies and solid tumors.
On May 4, 2026, ADC Therapeutics reported its first-quarter earnings. The company announced an earnings per share (EPS) of -$0.21, missing the analyst consensus estimate of -$0.19. This loss, however, shows an improvement compared to the loss of $0.36 per share reported in the same quarter of the previous year.
For the same quarter, the company’s revenue was $20.03 million, slightly beating the analyst estimate of $19.99 million. As highlighted by Zacks, this marks the fourth consecutive quarter that ADC Therapeutics has surpassed revenue estimates. This revenue figure is a decrease from the $23.03 million generated in the first quarter of 2025.
The company’s financial metrics show a negative Price-to-Earnings (P/E) ratio of -4.19, indicating it has not been profitable over the past year. A negative Debt-to-Equity ratio of -1.95 can mean that liabilities are greater than assets. However, a current ratio of 4.09 shows a strong ability to cover short-term debts.
Operationally, ADC Therapeutics maintains a solid cash position with $231 million in cash and equivalents as of March 31, 2026. This provides an expected cash runway at least into 2028. The company also expects to release important data from its LOTIS-5 and LOTIS-7 clinical trials by the end of the year.
